Story · Medicine & Biotech

Earnings roundup: Lilly’s unwavering momentum, Novartis’ rebound and GSK’s waiting game

1 outlet · first reported by BioPharma Dive 12d ago

Coverage, in order

  1. 12d ago
    BioPharma Dive indie
    Earnings roundup: Lilly’s unwavering momentum, Novartis’ rebound and GSK’s waiting game

    Lilly’s better-than-expected results allayed concerns — for now — over GLP-1 pricing pressure. Elsewhere, Novartis withstood a tumultuous quarter and GSK battled investor angst.

Alivewire groups outlets reporting the same story. Each headline links to the outlet that wrote it; nothing is republished here.